Alpha Tau Medical Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Alpha Tau Medical Ltd. on May 7, 2026, covering the month of May 2026. The filing serves to report a significant corporate development regarding the Company's Alpha DaRT® technology.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The primary material event reported is the successful treatment of the first pancreatic cancer patient in Italy using the Company's Alpha DaRT® technology. This treatment was administered at the University of Verona's Pancreas Institute.
Outlook, Risks, and Management Commentary
Management highlighted the successful clinical application of Alpha DaRT® in Italy as a key milestone. The filing includes a press release (Exhibit 99.1) detailing this achievement. No specific financial guidance, risk factors, or contingencies were detailed within the text of this specific Form 6-K.
Key Facts for Investor Verification
- Alpha Tau Medical Ltd. successfully treated its first pancreatic cancer patient in Italy with Alpha DaRT®.
- The treatment took place at the University of Verona's Pancreas Institute.
- The event was announced via a press release dated May 7, 2026.
- This filing contains no financial performance data or updated guidance.